TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1929681

Group type: EXPERIMENTAL
Intervention: Warfarin therapy
Number of subjects: 333

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Warfarin therapy with bleeding episode
Number of subjects: 333
Study: 6134481

Group type: EXPERIMENTAL
Intervention: Alfentanil 8 micrograms/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Methohexitone or Althesin anaesthesia
Number of subjects: 40
Study: 29223789

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 18

Group type: COMPARATOR
Intervention: Laser
Number of subjects: 18
Study: 28931194

Group type: EXPERIMENTAL
Intervention: Intracapsular radiofrequency ablation tonsillectomy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Subcapsular tonsillectomy
Number of subjects: 22
Study: 25446228

Group type: EXPERIMENTAL
Intervention: Oxytocin (OT)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Arginine vasopressin (AVP)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 29
Study: 23212802

Group type: EXPERIMENTAL
Intervention: Cystatin C > 2.04 mg/L
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: ESAM > 34 ng/mL
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 464
Study: 21548947

Group type: EXPERIMENTAL
Intervention: Short questionnaire (15 page)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Personalised reminder
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Long questionnaire (24 page)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Reminder packs
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Reminder postcards
Number of subjects: 1000
Study: 18420662

Group type: EXPERIMENTAL
Intervention: Self monitoring of blood glucose
Number of subjects: 184

Group type: COMPARATOR
Intervention: No monitoring (control)
Number of subjects: 184
Study: 16216315

Group type: EXPERIMENTAL
Intervention: MVAC (methotrexate 30 mg/m2 days 1, 15, and 22; vinblastine 3 mg/m2 days 2, 15, and 22; doxorubicin 30 mg/m2 day 2; cisplatin 70 mg/m2 day 2 q 4 weeks)
Number of subjects: 186

Group type: COMPARATOR
Intervention: TC (cisplatin 50 mg/m2 day 1 and topotecan 0.75 mg/m2 days 1‐3 q 3 weeks)
Number of subjects: 186

Group type: COMPARATOR
Intervention: C (cisplatin 50 mg/m2 q 3 weeks)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: MVAC, TC, and C
Number of subjects: 186
Study: 12663724

Group type: EXPERIMENTAL
Intervention: Once-daily oral etoposide (50 mg/m2/d)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Twice-daily oral etoposide (50 mg/m2/d)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Once-daily vs twice-daily oral etoposide
Number of subjects: 58
Study: 11382798

Group type: EXPERIMENTAL
Intervention: Dietary protein intake of 0.8 g protein.kg(‐1).day(‐1) for 14 weeks
Number of subjects: 10
Study: 9433633

Group type: EXPERIMENTAL
Intervention: New method for testing association of genetic markers with disease in nuclear families
Number of subjects: 0
Study: 8389572

Group type: EXPERIMENTAL
Intervention: Sodium dithiocarb (DDC)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 64
Study: 3538363

Group type: EXPERIMENTAL
Intervention: pindolol 10 mg once daily for 4 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: atenolol 100 mg once daily for 4 weeks
Number of subjects: 19
Study: 31280619

Group type: EXPERIMENTAL
Intervention: masitinib 4.5 mg/kg/d
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: masitinib 3.0 mg/kg/d
Number of subjects: 394

Group type: COMPARATOR
Intervention: riluzole + placebo
Number of subjects: 394

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 394
Study: 29661605

Group type: EXPERIMENTAL
Intervention: Alive multiprobiotic 'Symbiter' (concentrated biomass of 14 probiotic bacteria genera Bifidobacterium, Lactobacillus, Lactococcus, Propionibacterium) for 8 weeks
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Alive multiprobiotic 'Symbiter'
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 27455252

Group type: EXPERIMENTAL
Intervention: NIOR (+) diet for six months
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Cust (+) diet for six months
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: NIOR (−) diet for six months
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Cust (−) diet for six months
Number of subjects: 171
Study: 25041382

Group type: EXPERIMENTAL
Intervention: Electrical stimulation (0.04 ms duration, starting from 0 mA in increments of 0.2 mA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pressure algometry
Number of subjects: 0
Study: 23497788

Group type: EXPERIMENTAL
Intervention: DCS (50mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 21504954

Group type: EXPERIMENTAL
Intervention: Home-based physiotherapy (twice weekly for eight weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 30
Study: 18004495

Group type: EXPERIMENTAL
Intervention: Nursing intervention with telephone checkups twice a week
Number of subjects: 88
Study: 17075123

Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 1692

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1692
Study: 12639491

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-adjuvanted H5N3 A/Duck/Singapore/97 vaccine
Number of subjects: 0
Study: 10957701

Group type: EXPERIMENTAL
Intervention: Paracetamol and codeine suppository (60 mg codeine and 800 mg paracetamol) with standard premedication of intramuscular midazolam 0.08 mg/kg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo suppository and midazolam
Number of subjects: 90
Study: 8813040

Group type: EXPERIMENTAL
Intervention: Zidovudine plus didanosine
Number of subjects: 1102

Group type: EXPERIMENTAL
Intervention: Zidovudine plus zalcitabine
Number of subjects: 1102

Group type: COMPARATOR
Intervention: Zidovudine alone
Number of subjects: 1102
Study: 1534961

Group type: EXPERIMENTAL
Intervention: Paroxetine (30 mg/day) for 6 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amitriptyline (150 mg/day) for 6 weeks
Number of subjects: 0
Study: 3835918

Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control non-adenoidectomy group
Number of subjects: 155
Study: 29789100

Group type: EXPERIMENTAL
Intervention: TEXT ME text message support program
Number of subjects: 710

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 710
Study: 27658890

Group type: EXPERIMENTAL
Intervention: myo-inositol
Number of subjects: 74

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 74
Study: 23862643

Group type: EXPERIMENTAL
Intervention: Auditory brainwave entrainment using binaural beats around 2-8 Hz for eight weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group with no auditory stimulation
Number of subjects: 15
Study: 22658938

Group type: EXPERIMENTAL
Intervention: High-MUFA (HMUFA) diet
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Low-fat, high-complex carbohydrate diet supplemented with long-chain n-3 PUFA (LFHCCn-3)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control oil (LFHCC)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: High-SFA (HSFA) diet
Number of subjects: 84
Study: 19840889

Group type: EXPERIMENTAL
Intervention: Perhexiline
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 17681339

Group type: EXPERIMENTAL
Intervention: 6 punctures on the left ovary and 12 on the right
Number of subjects: 96

Group type: COMPARATOR
Intervention: 6 punctures on the right ovary and 12 on the left
Number of subjects: 96
Study: 16327580

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) at a low dose of 0.5 mg/kg divided in two equal doses
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 118
Study: 12817764

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active control
Number of subjects: 0
Study: 10802793

Group type: EXPERIMENTAL
Intervention: Zolmitriptan 10 mg
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Zolmitriptan 5 mg
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Zolmitriptan 5 mg and 10 mg
Number of subjects: 124
Study: 8627080

Group type: EXPERIMENTAL
Intervention: Stavudine (0.1, 0.5, 1.0, or 2.0 mg/kg/day)
Number of subjects: 15
Study: 1600040

Group type: EXPERIMENTAL
Intervention: Combined omeprazole (40 mg mane) and ranitidine (50 mg bolus followed by 12.5 mg/h)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg mane)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ranitidine (50 mg bolus followed by 12.5 mg/h)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6198914

Group type: EXPERIMENTAL
Intervention: 32% dextran 70 (n = 23)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 32% dextran 70 (n = 17)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (n = 21)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (n = 12)
Number of subjects: 44
Study: 31759891

Group type: EXPERIMENTAL
Intervention: Elagolix (oral, nonpeptide gonadotropin-releasing hormone antagonist)
Number of subjects: 1686
Study: 31013304

Group type: EXPERIMENTAL
Intervention: Variably-accelerated pattern search algorithm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single variable optimization based on Den Hartog formula
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ergodic search method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Integer programming method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional genetic algorithm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional pattern search algorithm
Number of subjects: 0
Study: 28056468

Group type: EXPERIMENTAL
Intervention: Supplemental Phonemic Awareness Curriculum (PAth to Literacy)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Vocabulary intervention (Story Friends)
Number of subjects: 104
Study: 25306932

Group type: EXPERIMENTAL
Intervention: Coping Skill Training (CST)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: 12-step facilitation (TSF)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Delayed Treatment Control (DTC)
Number of subjects: 85
Study: 23140112

Group type: EXPERIMENTAL
Intervention: Mindfulness-induction
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 97
Study: 21343146

Group type: EXPERIMENTAL
Intervention: Ad5-vectored HIV-1 vaccine
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Ad5-vectored HIV-1 vaccine (in subset with protective HLA types B27, B57, B58)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 18222010

Group type: EXPERIMENTAL
Intervention: Concomitant carboplatin and radiotherapy (50mg/m² IV infusion twice weekly, 54-72Gy, 30-40 fractions, 6-8 weeks)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Post-operative radiotherapy alone (54-72Gy, 30-40 fractions, 6-8 weeks)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 144
Study: 17058295

Group type: EXPERIMENTAL
Intervention: Robot-assisted Nissen fundoplication (RNF)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard laparoscopic Nissen fundoplication (LNF)
Number of subjects: 50
Study: 12913045

Group type: EXPERIMENTAL
Intervention: Overweight (BMI 25-30 kg/m²)
Number of subjects: 10537

Group type: EXPERIMENTAL
Intervention: Obese (BMI >30 kg/m²)
Number of subjects: 10537

Group type: EXPERIMENTAL
Intervention: Overweight and Obese
Number of subjects: 10537
Study: 10733441

Group type: EXPERIMENTAL
Intervention: Epoprostenol plus conventional therapy
Number of subjects: 111

Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 111
Study: 8939323

Group type: EXPERIMENTAL
Intervention: High-dose vitamin B12 injections
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 2
Study: 1413131

Group type: EXPERIMENTAL
Intervention: 30 minutes of extended verbal information
Number of subjects: 151

Group type: COMPARATOR
Intervention: Standard information of the department
Number of subjects: 151
Study: 2856949

Group type: EXPERIMENTAL
Intervention: Tamoxifen (30 mg daily for one year)
Number of subjects: 291

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 291
Study: 29456442

Group type: EXPERIMENTAL
Intervention: Matched thoracic spine manipulation
Number of subjects: 69

Group type: COMPARATOR
Intervention: Unmatched thoracic spine manipulation
Number of subjects: 69
Study: 27083430

Group type: EXPERIMENTAL
Intervention: Antiviral therapy (nucleotide/nucleoside analogues)
Number of subjects: 2557

Group type: COMPARATOR
Intervention: Adverse events (headache)
Number of subjects: 2557

Group type: COMPARATOR
Intervention: Adverse events (abdominal pain)
Number of subjects: 2557

Group type: COMPARATOR
Intervention: Adverse events (pharyngitis)
Number of subjects: 2557
Study: 26181088

Group type: EXPERIMENTAL
Intervention: Norethindrone acetate (5 mg/day) plus conjugated equine estrogens (0.625 mg/day)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Norethindrone acetate plus placebo
Number of subjects: 51
Study: 22327817

Group type: EXPERIMENTAL
Intervention: Ankaferd blood stopper (ABS) applied locally on extraction sockets
Number of subjects: 25

Group type: COMPARATOR
Intervention: Direct packing with gauze (Control group)
Number of subjects: 25
Study: 20554333

Group type: EXPERIMENTAL
Intervention: Recreation and walking program (EG)
Number of subjects: 59
Study: 19065856

Group type: EXPERIMENTAL
Intervention: Sustained spatial attention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Test stimuli at peri‐threshold, intermediate contrast levels
Number of subjects: 0
Study: 16841623

Group type: EXPERIMENTAL
Intervention: Bupropion XL (300-450 mg/day)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Escitalopram (10-20 mg/day)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study: 12801312

Group type: EXPERIMENTAL
Intervention: Ozone (0.2 ppm) exposure for 2 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Filtered air exposure for 2 hours
Number of subjects: 0
Study: 10327874

Group type: EXPERIMENTAL
Intervention: Reduction in sodium intake of 118 mmol
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Reduction in sodium intake
Number of subjects: 114
Study: 7547043

Group type: EXPERIMENTAL
Intervention: 4% amethocaine gel
Number of subjects: 94

Group type: COMPARATOR
Intervention: 5% EMLA cream
Number of subjects: 94
Study: 1687987

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Noxiptilin
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Dibenzepin
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Nomifensine
Number of subjects: 250
Study: 7046930

Group type: EXPERIMENTAL
Intervention: melphalan
Number of subjects: 31

Group type: COMPARATOR
Intervention: radioactive phosphorus
Number of subjects: 31
Study: 30644312

Group type: EXPERIMENTAL
Intervention: 10 mg seltorexant
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 20 mg seltorexant
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 40 mg seltorexant
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 28183335

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (50,000 IU weekly for 3 weeks, then 2000 IU daily until 1 year post ART initiation)
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Placebo regimen
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 4000
Study: 26843154

Group type: EXPERIMENTAL
Intervention: Soy isoflavones (80 mg aglycone equivalents)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Commercially produced S-(−)equol (40 mg)
Number of subjects: 28
Study: 24215991

Group type: EXPERIMENTAL
Intervention: Bilateral support to walk
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: No walking impairment
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Impaired walking, no aid
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 365
Study: 22585228

Group type: EXPERIMENTAL
Intervention: Rifaximin 25 mg/day for 5 days
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Rifaximin 100 mg/day for 5 days
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Rifaximin 100 mg/day for 2 days
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 20067456

Group type: EXPERIMENTAL
Intervention: Bupropion SR (150 mg twice daily)
Number of subjects: 234
Study: 16926046

Group type: EXPERIMENTAL
Intervention: Prenatal ultrasound scanning
Number of subjects: 0
Study: 15668857

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 473

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 473
Study: 12474512

Group type: EXPERIMENTAL
Intervention: Suture repair (Group I) for hernias between 5-25 cm²
Number of subjects: 2300

Group type: EXPERIMENTAL
Intervention: Mesh implantation (sublay) (Group II) for hernias larger than 25 cm²
Number of subjects: 2300

Group type: EXPERIMENTAL
Intervention: Mesh implantation (onlay) (Group II) for hernias larger than 25 cm²
Number of subjects: 2300

Group type: EXPERIMENTAL
Intervention: Laparoscopic approach (Group II) for hernias larger than 25 cm²
Number of subjects: 2300
Study: 9922309

Group type: EXPERIMENTAL
Intervention: Oral budesonide, 6 mg daily
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study: 7570133

Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 32

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 32
Study: 2270057

Group type: EXPERIMENTAL
Intervention: 1.2ml/kg alcohol with exteroceptive contextual cues (AL-EXPT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1.2ml/kg alcohol in a context not normally associated with alcohol (AL-UNEXPT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nonalcoholic beverage believed to be alcohol (placebo)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Juice in the alcohol-unexpected context
Number of subjects: 40
Study: 7366836

Group type: EXPERIMENTAL
Intervention: Metrizamide (Amipaque)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Meglumine metrizoate (Isopaque Cerebral)
Number of subjects: 308
Study: 30696443

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Occlusal appliance (OA)
Number of subjects: 57
Study: 28106611

Group type: EXPERIMENTAL
Intervention: High-dose fentanyl
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Low-dose fentanyl
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 16
Study: 26027628

Group type: EXPERIMENTAL
Intervention: Half-dose tenecteplase (TNK) post-amendment (50% reduction in dose)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Standard dose tenecteplase (TNK) pre-amendment
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Half-dose tenecteplase (TNK) post-amendment
Number of subjects: 135
Study: 24118794

Group type: EXPERIMENTAL
Intervention: Lowered endothelial function measured by peripheral arterial tonometry (PAT)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: HDL cholesterol
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Male sex, body mass index, current smoking
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Stepwise multivariable regression model
Number of subjects: 312
Study: 21889801

Group type: EXPERIMENTAL
Intervention: Ahmed‐FP7 valve
Number of subjects: 238

Group type: COMPARATOR
Intervention: Baerveldt‐350 implant
Number of subjects: 238
Study: 18783797

Group type: EXPERIMENTAL
Intervention: Infant Behavioral Assessment and Intervention Program (IBAIP)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 176
Study: 16740395

Group type: EXPERIMENTAL
Intervention: Group 1: 15 trials on 1 day
Number of subjects: 26

Group type: COMPARATOR
Intervention: Group 2: 5 trials on each of three consecutive days
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 26
Study: 12971512

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) - Group 1: intravenous loading dose of 140 mg/kg followed by 70 mg/kg every four hours for up to 18 doses
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) - Group 2: a single intravenous loading dose followed by oral NAC in the same amount as for Group 1
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) - Group 3: regimen identical to Group 1 except that oral NAC was administered after the first 24 hours
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo plus artesunate
Number of subjects: 108
Study: 10953124

Group type: EXPERIMENTAL
Intervention: Intravesical resiniferatoxin (10 nM)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo saline solution
Number of subjects: 18
Study: 8630635

Group type: EXPERIMENTAL
Intervention: Meloxicam 7.5 mg once daily
Number of subjects: 336

Group type: COMPARATOR
Intervention: Diclofenac 100 mg slow release once daily
Number of subjects: 336
Study: 1442992

Group type: EXPERIMENTAL
Intervention: Depot leuprolide
Number of subjects: 270

Group type: COMPARATOR
Intervention: Danazol
Number of subjects: 270
Study: 6563534

Group type: EXPERIMENTAL
Intervention: Intervention group (N = 42)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (N = 44)
Number of subjects: 86
Study: 3578733

Group type: EXPERIMENTAL
Intervention: Magill tracheal tubes
Number of subjects: 100

Group type: COMPARATOR
Intervention: Mallinckrodt tracheal tubes
Number of subjects: 100
Study: 29274118

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prednisone (PRED)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HD-MTX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Escalating doses of methotrexate (C-MTX)
Number of subjects: 0